Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Heron Therapeutics (HRTX) over the last 12 years, with Sep 2025 value amounting to $2.5 million.

  • Heron Therapeutics' Change in Accured Expenses rose 170.87% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 463.54%. This contributed to the annual value of $330,000 for FY2024, which is 107.87% up from last year.
  • Latest data reveals that Heron Therapeutics reported Change in Accured Expenses of $2.5 million as of Q3 2025, which was up 314.25% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Change in Accured Expenses registered a high of $13.5 million during Q4 2022, and its lowest value of -$7.7 million during Q4 2021.
  • Its 3-year average for Change in Accured Expenses is $290,000, with a median of $520,000 in 2023.
  • Per our database at Business Quant, Heron Therapeutics' Change in Accured Expenses soared by 275.31% in 2022 and then slumped by 1,297.69% in 2024.
  • Over the past 5 years, Heron Therapeutics' Change in Accured Expenses (Quarterly) stood at -$7.7 million in 2021, then soared by 275.31% to $13.5 million in 2022, then crashed by 108.56% to -$1.2 million in 2023, then surged by 233.85% to $1.5 million in 2024, then spiked by 170.87% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, -$1.2 million for Q2 2025, and $5.7 million during Q1 2025.